Skip to main content

About Doured Daghistani


Doured Daghistani, M.D., is a pediatric oncologist/hematologist at Miami Cancer Institute, a part of Baptist Health South Florida. He is also medical director of pediatric oncology at Baptist Children’s Hospital. Dr. Daghistani received his medical degree from the University of Damascus in Syria and completed an internship at Mouassa Hospital, Damascus, Syria Centre Hospitalier de Mamers, in France. He later completed a fellowship in pediatric hematology/oncology at the University of Miami/Jackson Memorial Hospital. He is Board-certified by the American Board of Pediatrics and holds sub-Board certification in pediatric hematology/oncology.

Positions

2014 - Present Chief, Pediatric Hematology and Oncology, Baptist Health South Florida ‐ Miami Cancer Institute
to
2014 - Present Medical Director of Pediatric Hematology and Oncology, Baptist Health South Florida ‐ Baptist Hospital
to
1996 - 2014 Physician, Oncology Hematology Radiation Care, LLC ‐ Advanced Medical Specialties
to
1991 - 1996 Physician, Jackson Memorial Hospital ‐ Dept. of Pediatrics
to
1991 - 1996 Assistant Professor of Clinical Pediatrics, University of Miami School of Medicine ‐ Division of Pediatric Hematology/Oncology
to
1989 - 1990 Assistant Professor of Pediatrics, Kuwait University School of Medicine
to

Disciplines

Grants

2008 - 2100 Umbrella Long-Term Follow-Up Protocol
Children’s Oncology Group - NCT00736749
Role: Site PI
2006 - 2100 Renal Tumors Classification, Biology, and Banking Study
Children’s Oncology Group - NCT00898365
Role: Site PI
2000 - 2100 Biomarkers in Tumor Tissue Samples from Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
Children’s Oncology Group - NCT00904241
Role: Site PI
2017 - 2028 Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Children’s Oncology Group - NCT03007147
Role: Site PI
2020 - 2027 Patients with Tumors Harboring RET Gene Alterations
National Cancer Institute - NCT04320888
Role: Site PI
2020 - 2027 Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute - NCT04284774
Role: Site PI
2019 - 2027 A Study to Investigate Blinatumomab in Combination with Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
National Cancer Institute - NCT03914625
Role: Site PI
2019 - 2027 Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Children’s Oncology Group - NCT03959085
Role: Site PI
2017 - 2027 Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients with Germ Cell Tumors
Children’s Oncology Group - NCT03067181
Role: Site PI
2020 - 2025 Ivosidenib in Treating Patients with Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute - NCT04195555
Role: Site PI
2015 - 2025 Every Child for Younger Patients with Cancer
Children’s Oncology Group - NCT02402244
Role: Site PI
2014 - 2025 Utilizing Response and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Children’s Oncology Group - NCT02176967
Role: Site PI
2019 - 2024 Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients with Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
National Cancer Institute - NCT03907488
Role: Site PI
2016 - 2024 Combination Chemotherapy with or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
National Cancer Institute - NCT02567435
Role: Site PI
2004 - 2020 Key Adverse Events After Childhood Cancer
Children’s Oncology Group - NCT00082745
Role: Site PI
1994 - 1995 Hoffman La Roche
Hoffman La Roche
1992 - 1993 Immunex Corporation
Immunex Corporation
Role: PI
1991 - 1992 American Cancer Society Institutional Grant
American Cancer Society
Role: PI
$
to
Enter a valid date range.

Professional Service and Affiliations

1992 - Present Member, American Society of Clinical Oncology
1992 - Present Member, American Society of Hematology
1992 - Present Member, American Society of Pediatric Hematology/Oncology
1992 - Present Member, Children’s Oncology Group
1992 - Present Member, The Greater Miami Pediatric Society
1986 - Present Member, American Academy of Pediatrics
2015 - 2015 President of Medical Staff, Baptist Hospital
2008 - 2012 Chairman, Baptist Children's Hospital Executive Board
2008 - 2012 Vice President, Baptist Hospital Medical Staff
2008 - 2012 Secretary/Treasurer, Baptist Hospital Medical Staff
1994 - 1996 University Committee and Administrative Responsibilities, University of Miami Standing Committee for Research Support Services
1993 - 1996 Medical Consultant, H.E.D.S.S. UP (Health Education for Students by Students)
to
Enter a valid date range.

Honors and Awards

  • Faculty Teaching Award for Best Clinical Instructor, University of Miami Department of Pediatrics 1994-1995
  • H.E.D.S.S. UP Recognition Award (Local Community Services)

Education

to
1986 - 1989 Fellow, University of Miami/Jackson Memorial Hospital ‐ Pediatric Hematology/Oncology
to
1983 - 1986 Pediatric Resident, University of Miami/Jackson Memorial Hospital
to
1982 - 1982 Intern, Centre Hospitalier de Mamers, France
to
1981 - 1982 Moussa Hospital, Damascus, Syria
to
1975 - 1981 MD, University of Damascus, Syria
to
1971 - 1975 Baccaloria, Lycee of Damascus, Syria
to

Links

Contact Information

Miami Cancer Institute
8900 N. Kendall Drive
Miami, FL 33176

Articles (9)

Posters (7)

Abstracts (9)